Thermo Fisher Scientific Second Quarter 2025 Financial Results

This document presents the second quarter 2025 financial results for Thermo Fisher Scientific Inc., a global leader in scientific services. It details the company's revenue growth of 3% to $10.85 billion and a 6% increase in GAAP diluted earnings per share. The report highlights operational performance, strategic innovations like new scientific instruments and bioreactor portfolios, and the expansion of partnerships, including the acquisition of Sanofi's sterile fill-finish site. Furthermore, the document provides comprehensive financial statements, including condensed consolidated statements of income, balance sheets, and cash flows, along with reconciliations of non-GAAP financial measures used by management to assess performance. The company also reiterates its mission to enable customers in making the world healthier, cleaner, and safer, emphasizing its diverse range of industry-leading brands.

There are no comments yet.

Please log in to write the first comment.